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Allogeneic Mesenchymal Stem Cells for Treatment of
AKI after Cardiac Surgery
Madhav Swaminathan,1 Mark Stafford-Smith,1 Glenn M. Chertow,2 David G. Warnock,3
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ABSTRACT
AKI after cardiac surgery remains strongly associated with mortality and lacks effective treatment or prevention.
Preclinical studies suggest that cell-based interventions may inﬂuence functional recovery. We conducted a phase
2, randomized, double-blind, placebo-controlled trial in 27 centers across North America to determine the safety
and efﬁcacy of allogeneic human mesenchymal stem cells (MSCs) in reducing the time to recovery from AKI after
cardiac surgery. We randomized 156 adult subjects undergoing cardiac surgery with evidence of early AKI to
receive intra-aortic MSCs (AC607; n=67) or placebo (n=68). The primary outcome was the time to recovery of
kidney function deﬁned as return of postintervention creatinine level to baseline. The median time to recovery of
kidney function was 15 days with AC607 and 12 days with placebo (25th, 75th percentile range, 10–29 versus 6–
21, respectively; hazard ratio, 0.81; 95% conﬁdence interval, 0.53 to 1.24; P=0.32). We did not detect a signiﬁcant
difference between groups in 30-day all-cause mortality (16.7% with AC607; 11.8% with placebo) or dialysis
(10.6% with AC607; 7.4% with placebo). At follow-up, 12 patients who received AC607 and six patients who
received placebo had died. Rates of other adverse events did not differ between groups. In these patients with
AKI after cardiac surgery, administration of allogeneic MSCs did not decrease the time to recovery of kidney
function. Our results contrast with those in preclinical studies and provide important information regarding the
potential effects of MSCs in this setting.
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AKI after cardiac surgery is strongly associated with adverse outcomes, including early mortality and late progression to CKD.1–3
In addition, rates of AKI after cardiac surgery continue to increase, and the burden on health care resources is signiﬁcant.4
The cardiac surgical setting is appealing to AKI research, because
the timing of insult is deﬁned, patients are carefully followed while
remaining in the acute care setting, and patients are typically seen
in follow-up over the months after discharge. A substantial body
of work has helped to characterize postcardiac surgery AKI,
including its incidence, time trends, risk factors, predictive
algorithms, and clinical consequences. However, despite the
breadth of knowledge of AKI and recent consensus in terminology, successful preventive strategies and therapeutic options remain elusive. Given the poor short- and long-term
outcomes in patients with postcardiac surgical AKI, there is
considerable interest in identifying and evaluating interventions to not only prevent AKI but also, enhance recovery of
kidney function.5,6
Several investigators have previously examined the potential
value of bone marrow–derived mesenchymal stem cells
(MSCs) in facilitating repair in injured kidney tissue.7–9 In
the setting of acute injury, a number of organs, including the
kidney, increase expression of stromal derived factor-1, which
by its cognate receptor, CXCR4, on MSCs provides a homing
signal, enabling MSC migration to the site of injury. It has been
proposed that these stimulated MSCs secrete paracrine effector
molecules, including endothelial and epithelial growth factors
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Signiﬁcance Statement
AKI is a major complication of cardiac surgery. Although effective
preventive strategies remain elusive, cell-based therapies may inﬂuence functional recovery. We conducted a phase 2 multicenter
clinical trial of 156 cardiac surgery subjects with early postoperative
AKI to determine whether mesenchymal stem cells (MSCs) enhance
functional kidney recovery after cardiac surgery. We found no difference in time to kidney recovery, rate of dialysis, 30-day mortality,
or adverse events. These results contrast with the beneﬁcial effects
associated with MSCs in preclinical studies of AKI and raise questions
regarding their clinical utility to facilitate recovery of AKI in the
setting of cardiac surgery.

and anti-inﬂammatory cytokines that collectively encourage
the injured renal tubule epithelial cells to pursue a path of
cell division and recovery versus an unaltered course characterized by apoptosis and ultimate ﬁbrosis.10 Since the early
description of the putative role of bone marrow–derived
stem cells in repair of ischemia and tubular toxin–mediated
AKI,11 several preclinical studies have established the potential
role of MSCs in AKI. Several reviews on the use of MSCs in
animal models concluded that MSCs could indeed improve
kidney function after AKI.12,13 The few clinical applications
of MSCs in kidney disease reported to date have focused on
transplant recipients, with one study reporting faster recovery
of kidney function among patients treated with MSCs.14
We conducted a multicenter, randomized, controlled trial

Figure 1. CONSORT (Consolidated Standards of Reporting Trials) diagram.
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evaluating the safety and efﬁcacy of allogeneic MSCs (AC607;
AlloCure Inc., Burlington, MA) in patients with AKI after cardiac
surgery to test the hypothesis that MSCs reduce the time to recovery
of kidney function after postoperative AKI, deﬁned as the return of
postinterventional serum creatinine to the baseline presurgery level
(trial registration: ClinicalTrials.gov no. NCT01602328).

RESULTS
Baseline and Surgical Characteristics

A total of 26,548 patients underwent study-qualifying cardiac operations; 1990 were eligible, and 156 patients were randomized into
the study (Figure 1 and Supplemental Table 1). The protocoldeﬁned incidence of AKI was 7.5%. Twenty-one randomized patients (ten AC607; 11 placebo) were not dosed, and 15 withdrew
from the study (seven AC607; eight placebo). Sixty patients in
each group completed 30 days of follow-up, and 57 in each group
were followed for 90 days. Baseline characteristics of the study
population are summarized in Table 1. More than one half of all

patients had impaired kidney function at baseline. The median
cardiopulmonary bypass (CPB) time and the time from end of
surgery to study drug administration were longer in the AC607
group; otherwise, surgical data were comparable between groups.
The Data Monitoring Committee (DMC) reviewed the
safety data at prespeciﬁed intervals after 34, 50, and 119 patients
were recruited. After the ﬁnal meeting with 75% patient accrual, the DMC recommended the trial be halted due to futility.
The results included here represent all data collected during the
study, including additional follow-up information that was not
available to the DMC at the time of their recommendation.
Outcomes

The primary analysis showed no signiﬁcant difference in time
to recovery of kidney function, with a median of 15 (25th, 75th
percentile range, 10–29) days in the AC607 group versus 12
(interquartile range [IQR], 6–21) days in the placebo group
(hazard ratio, 0.81; 95% conﬁdence interval, 0.53 to 1.24; P=0.32)
(Figure 2). Thirty-nine of 66 patients (59%) in the AC607 group
and 46 of 68 (68%) in the placebo group recovered to baseline
kidney function; all recovery of kidney function occurred by day 35 poststudy treatment.
Table 1. Baseline characteristics and surgical information
There were no signiﬁcant differences between
Variable
AC607, n=67 Placebo, n=68
groups in the secondary outcomes of all-cause
Age, yr, mean6SD
65.6611.9
67.069.9
mortality or provision of dialysis (Table 2).
Sex, n
Similarly, there were no differences between
Women
23
12
groups in peak rise in serum creatinine, area
Men
44
56
under the curve for serum creatinine at day 30,
Weight, kg, mean6SD
90.5621.0
91.6621.5
longer-term kidney function, in-hospital morHeight, cm, mean6SD
169.0610.4
172.569.8
tality, intensive care length of stay, or total hosRace, n
pital length of stay (Table 2).
White/European
55
58
Using the alternative deﬁnition of recovery
Black/African
6
8
(to baseline serum creatinine +0.2 mg/dl), the
Other
6
2
mediantimetorecoveryofkidney functionwas
Diabetes, n
27
33
Hypertension, n
56
58
5.5 (IQR, 3.0–17.0) days in the AC607 group
CHF, n
29
30
and 4.0 (IQR, 2.0–10.0) days in the placebo
COPD, n
10
9
group (hazard ratio, 0.70; 95% conﬁdence inPreoperative albuminuria, n
7
6
terval, 0.49 to 1.02; P=0.06), and the proporCKD, n
tion of patients who recovered kidney function
Stage 1
12
8
was 82% in the AC607 group and 91% in the
Stage 2
22
23
placebo group. Exploratory prespeciﬁed subStage 3
29
34
group analyses on the basis of duration of CPB
Stage 4
4
3
(.120 or ,120 minutes), timing of dosing
Baseline eGFR, ml/min, mean6SD
61626
59624
(,24, 24–36, and .36 hours), baseline
Preoperative SCr, mg/dl, mean6SD
1.360.6
1.460.6
Pretreatment SCr, mg/dl, mean6SD
2.160.7
2.260.6
eGFR ($60 versus ,60 ml/min), study site,
Type of surgery, n
sex, or diabetes yielded results consistent with
CABG + valve
13
19
the primary efﬁcacy analysis (Figure 3).
CABG only
18
25
Atotal of 12 patients received dialysis (seven
Valve only
31
22
AC607; ﬁve placebo), and 11 died (six AC607;
Other
5
2
ﬁve placebo) within 30 days of treatment
Reoperative procedure, n
15
12
(Table 2). By the end of study follow-up, 12
Elective procedure, n
43
48
patients on AC607 and six patients on plaCPB time, min, mean6SD
168.1684.2
149.0670.2
cebo had died; the range of time to death
Time from end of surgery to study treatment, h, mean6SD
36.9610.1
35.5610.5
after study treatment was 0–219 days in the
CHF, congestive heart failure; COPD, chronic obstructive lung disease; SCr, serum creatinine; CABG,
AC607 group and 9–85 days in the placebo
coronary artery bypass graft.
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Figure 2. Primary end point: no difference between groups in
cumulative incidence curves for time to kidney recovery.

group (Supplemental Material and Supplemental Table 2). There
were no adverse events (AEs) of special interest or AEs that led to
discontinuation of study treatment (Table 3). Similarly, there were
no reports of development of cancer or manifestations of ectopic
MSC differentiation. Data pertaining to treatment emergent serious AEs up to 90 days post-treatment are provided in Supplemental Table 3. The groups were comparable in terms of vital signs and
clinical laboratory results (Supplemental Tables 4 and 5).

DISCUSSION

In this phase 2, multicenter, randomized, controlled trial, we
found that treatment of early postcardiac surgery AKI with
MSCs did not reduce the time to recovery of kidney function,
provision of dialysis, or mortality compared with placebo.

CLINICAL RESEARCH

Although not statistically signiﬁcant, there were numerically
more patients treated with AC607 who received dialysis or
died, and there was a longer time to recovery of kidney function in either the primary analysis or a sensitivity analysis
with a modiﬁed deﬁnition of the primary outcome.
AKI is a common complication of cardiac surgery, has been
shown consistently to be associated with morbidity and mortality, consumes precious health care resources, and has been
increasing in incidence over the last several decades.4 Cardiac
surgery–associated AKI is an appropriate model to test interventions aimed at either mitigating injury or accelerating recovery, because the timing of the insult is predictable and
because patients can be readily followed during their inpatient
recovery from surgery. Most interventional studies of prevention strategies have failed to show any signiﬁcant reduction in
incidence or severity of AKI, most likely due to the many
potential mechanisms of cardiac surgery–related injury and
the low number of events compromising statistical power. The
advantage of studying the recovery of kidney function after
proven AKI is in the targeting of patients who are more likely
to have an adverse clinical outcome. Strategies that promote
endogenous repair or that limit further injury may be as or
more effective than those that focus purely on prevention.6
The ability to mobilize endogenous progenitor cells that can
mitigate injury and participate in repair is well described.15,16
However, clinically relevant injury could overwhelm endogenous
repair mechanisms. Studies have, therefore, focused on how injured organs may be supplied with progenitor cells by either stimulating mobilization of endogenous stores or administration of
exogenous cells. Bone marrow–derived progenitor cells have been
known to play an important role in repair and recovery from

Table 2. Secondary and exploratory outcomes
Parameter
Secondary outcomes
All-cause mortality or dialysis, n (%)
Day 30
Day 90
All-cause mortality, n (%)
Day 30
Day 90
3 yr
In-hospital mortality, n (%)
Dialysis at day 30, n (%)
Exploratory outcomes
Peak rise in SCr, mg/dl, mean6SD
AUC of SCr, mg/dl 3 h, mean6SD
eGFR, ml/min, mean6SD
Baseline
6 mo
1 yr
ICU length of stay, d, mean6SD
Hospital length of stay, d, mean6SD
Hospital readmission within 30 d, n (%)a

AC607, n=66

Placebo, n=68

Mean Difference (95% CI)

11 (16.7)
12 (18.2)

8 (11.8)
9 (13.2)

4.9% (211.7 to 21.9)
4.9% (211.7 to 21.9)

6 (9.1)
8 (12.1)
12 (18.2)
7 (10.6)
7 (10.6)

5 (7.4)
6 (8.8)
6 (8.8)
4 (5.9)
5 (7.4)

1.7% (215.1 to 19.0)
3.3% (213.4 to 20.4)
9.4% (27.3 to 26.2)
4.7% (212.1 to 21.9)
3.3% (213.5 to 20.4)

1.5961.27
296.96322.8

1.3461.43
205.06241.5

0.25 (20.21 to 0.72)
92.0 (25.3 to 189.2)

61.4626.2
62.1625.2
52.0626.2
16.4646.7
19.5615.4
17/54 (31.5)

58624.2
58.2620.1
55.7619.7
7.067.2
16.3610.6
17/61 (27.9)

9.4 (22.1 to 20.9)
3.1 (21.5 to 7.8)
3.6% (214.7 to 21.7)

95% CI, 95% conﬁdence interval; SCr, serum creatinine; AUC, area under curve; ICU, intensive care unit.
a
Denominator includes only patients discharged within 30 d of study treatment.
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Figure 3. Exploratory subgroup analyses were consistent with the primary efﬁcacy analysis. (A) Duration of CPB, (B) timing of dosing, (C)
sex, (D) baseline eGFR, and (E) diabetes.

injury in several organs, including the kidney.12 MSCs are multipotent, nonhematopoietic stromal cells that reside in the perivascular niches of various organs; can form bone, cartilage, and fat;
and can participate in repair of injured tissue principally through
264
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paracrine mechanisms.9 Bone marrow–derived MSCs have been
shown to reduce the severity of experimental kidney injury and
accelerate recovery at variable rates depending on the delivery
route and timing of administration relative to the injury.12
J Am Soc Nephrol 29: 260–267, 2018
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Table 3. Treatment emergent AEs up to 30 d post-treatment
Parameter

AC607, n=67

Placebo, n=68

Patients with at least one TEAE (%)
At any time after study drug
During hospitalization
From discharge to day 90
Patients with at least one study drug–related TEAE (%)
Patient with at least one serious TEAE (%)
Patients with at least one TEAE leading to death (%)
Patients with at least one TEAE leading to treatment discontinuation (%)
Patients with at least one AE of special interest (%)

63 (94.0)
61 (91.0)
25/55 (45.5)
7 (10.4)
31 (46.3)
7 (10.4)
0
0

65 (95.6)
59 (86.8)
29/61 (47.5)
6 (8.8)
30 (44.1)
5 (7.4)
0
0

TEAE, treatment emergent adverse event.

We conducted this multicenter, phase 2 trial with the objective of assessing the effect of allogeneic MSCs on functional
recovery of the kidneys after clinically relevant postoperative
AKI. The absence of a signiﬁcant recovery signal after AKI in
patients treated with MSCs compared with placebo may be
attributable to several factors. First, MSCs could be less effective
in treating than in preventing AKI, which was also suggested
by the difference between this study and a small phase 1 study
in which 16 high-risk patients given MSCs before cardiac surgery had a lower incidence of postoperative AKI than a historical
control.13,17 Second, mechanisms of cardiac surgery–related
injury and recovery may be distinct from rodent models of
ischemia reperfusion, and the complexity of the postcardiac
surgery clinical setting may hinder our ability to observe a
modest clinical effect with MSCs or other agents.18,19 Third,
longer durations of CPB in the MSC group might have
masked a beneﬁcial effect, and some patients in this trial may
have had continuing renal insults (e.g., infection, low cardiac
output, or inﬂammation) that counterbalanced any beneﬁcial
effect of MSCs administered at a single time point along the
injury continuum. In addition, any signiﬁcant recovery signal
may have been insufﬁcient to be clinically evident, limited
to a small subset of patients with AKI and a suitable biochemical environment compatible with MSC-mediated repair, or obscured by the complexities of their postoperative
course. Another potential reason that the therapy failed is
because renal blood ﬂow may be decreased during this phase
of postcardiac AKI, thus limiting the delivery of the MSCs to
the kidney. Furthermore, many of the patients in this study
had impaired kidney function before surgery, and in the setting of already compromised kidney function, any beneﬁcial
effect of mesenchymal stromal cells could be attenuated. Finally, the sample size may have been insufﬁcient to detect a
small but meaningful acceleration of kidney recovery. However, the observed data and ﬁndings of our sensitivity analysis
do not suggest a strong likelihood of beneﬁt. Finally, we
should consider the possibility that bone marrow–derived
MSCs could induce harm, thereby delaying recovery—precisely
the opposite of what we had hypothesized. The lack of a beneﬁcial effect of MSCs has been shown in some clinical settings,
especially those where chronic inﬂammation was a signiﬁcant
J Am Soc Nephrol 29: 260–267, 2018

underlying modiﬁer, such as rheumatoid arthritis or inﬂammatory bowel disease.20,21 Although considered immunoprivileged,
human MSCs can have signiﬁcant in vivo immunomodulatory
effects or may even become immunogenic on differentiation.
The biologic activity of MSCs seems to be dependent on
the underlying inﬂammatory state, such that, in the presence
of proinﬂammatory conditions, MSCs can differentiate into
an anti-inﬂammatory phenotype and vice versa. It is possible
that the proinﬂammatory phenotype may contribute to AKI
as suggested by preclinical and clinical studies of MSCs in
kidney transplantation.22–24 Although we do not have data
on either biomarkers of chronic inﬂammation or differentiation of administered MSCs, it could be speculated that
these factors may have played a role in mitigating a beneﬁcial
effect of MSCs in our patient population or even exerted a
negative inﬂuence.
Among the strengths of this study was its rigorous design of a
treatment strategy for AKI in a relatively homogenous population of patients undergoing cardiac surgery. However, there
are some important limitations associated with the use of human allogeneic MSCs and their administration. One assumption in this trial was that the delivered MSCs were sufﬁcient and
viable at the time of administration. The dose used in this trial
(23106 MSCs per 1 kg) is consistent with what has been used
in other clinical settings and supported by both preclinical and
phase 1 data. Cell viability was tested during the manufacturing procedure, before storage in inventory, after post-thaw reconstitution in an experimental setting, and after the shipping of
AC607 to validate the shipping containers. During the study,
quality control testing was performed at each enrolling site to
ensure that reconstitution protocols were strictly followed and
yielded a ﬁnal product that met the release speciﬁcations. After
the termination of the study, viability and cell count studies were
performed on returned site inventory before destruction. In all
cases, cell viability ranged between 93% and 96%. As a result, we
presume that the majority of cells were viable at the time of
administration. The intra-arterial route was selected to maximize the likelihood of exposure of injured kidneys to the delivered MSC population in the ﬁrst pass and minimize ﬁltration
in the lungs, although we were unable to determine amount and
distribution of MSCs to the kidneys. Preclinical studies indicate
Mesenchymal Stem Cells and AKI
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that MSCs exert a beneﬁcial effect on the kidneys in ischemiareperfusion models via paracrine effects, even when administered MSCs are not seen to persist in host kidney tissue.9 We
are, therefore, conﬁdent that the intra-arterial route was the
optimal method for ensuring maximal delivery of viable
MSCs in sufﬁcient numbers to injured kidneys. It is possible
that intra-arterial administration might have resulted in vascular injury or cholesterol embolization in some patients,
although one would expect similar effects in patients randomized to both groups.
In summary, in a phase 2, multicenter, randomized, controlled trial, we found no signiﬁcant difference in time to recovery of kidney function after treatment of early postoperative
AKI with allogeneic MSCs compared with placebo. There were
also no signiﬁcant differences noted in any of the secondary
outcomes, although numerical imbalances favored placebo.
These results contrast with the favorable effects of MSCs in
preclinical studies and could be attributed to overwhelming or
ongoing injury, an insufﬁcient or undetectable beneﬁcial effect,
or possible harm. Despite the potential for beneﬁt suggested by
preclinical studies and relative safety of early-phase human
trials, several unanswered questions, such as optimal timing,
preparation, and method of delivery and whether any subsets of
patients may beneﬁt, would need to be addressed before continued development of MSCs for the treatment of established
AKI in patients undergoing cardiac surgery.

CONCISE METHODS
In accordance with the International Conference on Harmonization Good Clinical Practice guidelines, we conducted this phase 2,
randomized, double-blind, placebo-controlled trial in patients undergoing cardiac surgery with laboratory evidence of postoperative
AKI after site-speciﬁc regulatory approval in 27 tertiary care institutions in the United States and Canada from January 10, 2013 to
March 30, 2014.
We included adults (.21 years of age) undergoing cardiac surgery
using CPB who had a baseline serum creatinine measured within 30
days before surgery and who developed postoperative AKI (deﬁned
as a postoperative rise in serum creatinine .0.5 mg/dl from baseline
within 48 hours of removal from CPB). We excluded patients with
stage 5 CKD, active cancer or active treatment for cancer, surgery for
thoracoabdominal aortic aneurysm, presence of a medical condition
or device that would preclude or compromise femoral artery catheter
placement, or current or expected receipt of dialysis within 24 hours
of enrollment or dosing. All inclusion and exclusion criteria are provided in Supplemental Table 1.
We randomized enrolled subjects to receive AC607 (23106 cells
per 1 kg body weight) or placebo in a 1:1 ratio. We performed laboratory assessments at screening, daily during the postoperative hospital stay from the day of randomization to discharge, and at 30 and
90 days after study drug administration.
We administered AC607 or placebo as a single dose within 48 hours
of removal from CPB via an intra-aortic catheter placed in the femoral
266
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artery with the tip located proximal to the origin of the renal arteries.
AC607 was manufactured, processed, packaged, and labeled by Lonza
Walkersville, Inc. (Walkersville, MD). Clinical trials teams at each
institution were blinded to the preparation of AC607 or placebo.
The primary end point was the time to recovery of kidney function
after postoperative AKI deﬁned by the time in days from dosing to the
ﬁrst of two postdosing serum creatinine samples that returned to the
patient’s baseline level. Secondary efﬁcacy end points included allcause mortality or provision of dialysis at 30 and 90 days poststudy
drug administration, all-cause mortality at 30 and 90 days postadministration, and proportion of patients who required dialysis during
the 30-day evaluation period.
We performed safety and efﬁcacy analyses on all patients who
underwent cardiac surgery, provided informed consent, and were
treated with AC607 or placebo. We constructed Kaplan–Meier product limit plots and determined relative hazard (AC607 versus placebo) using proportional hazards (Cox) regression with treatment
group as a dependent variable. We calculated the difference between
treatment groups in proportions using the exact Clopper–Pearson
methodology. We conducted all statistical analyses using SAS software, version 9.2 or higher (SAS Institute, Cary, NC).
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